You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 277 No. 7, February 19, 1997 TABLE OF CONTENTS
  JAMA
  •  Online Features
  From the Centers for Disease Control and Prevention
 This Article
 •Excerpt
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Paralytic Poliomyelitis—United States, 1980-1994

JAMA. 1997;277(7):525-526.


References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.


1. ACIP. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine—recommendations of the Advisory Committee on Immunization Practices. MMWR 1997;46(no. RR-3).
2. CDC. Poliomyelitis—United States, 1975-1984. MMWR 1986;35:180-2. PUBMED
3. CDC. Certification of poliomyelitis eradication--the Americas, 1994. MMWR 1994;43:720-2. PUBMED
4. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA 1996;276:967-71. FREE FULL TEXT
5. Prevots DR, Sutter RW, Quick L, Izurieta H, Strebel PM. Vaccine-associated paralytic poliomyelitis in the United States, 1980-1994: current risk and potential impact of proposed sequential schedule of IPV followed by OPV [Abstract]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana: American Society for Microbiology, 1996:179.
6. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991: implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med 1994;148:479-85. FREE FULL TEXT
7. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virusassociated disease. Clin Infect Dis 1992;14:568-79. PUBMED
8. Orenstein WA, Wassilak SGF, Deforest A, et al. Seroprevalence of poliovirus antibodies among Massachusetts schoolchildren. In: Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy [Abstract]. Washington, DC: American Society for Microbiology, 1988:198.
9. Kelley PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ. The susceptibility of young adult Americans to vaccine-preventable infections: a national serosurvey of US Army recruits. JAMA 1991;266:2724-9. FREE FULL TEXT
10. CDC. Mandatory reporting of infectious diseases by clinicians. MMWR 1990;39(no. RR-9):1-17. PUBMED
* Acute onset of flaccid paralysis in one or more limbs with decreased or absent tendon reflexes in the affected limbs without other apparent cause and without sensory or cognitive loss (as reported by a physician).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.